While Indianapolis-based Eli Lilly has criticized moves by Indiana's Republican lawmakers and leaders over the years, the company's CEO is backing the president...

Last month, during a quarterly conference call—as Johnson & Johnson considered its future beyond the separation of its consumer health unit—Chief Financial Offic...

After 16 years on the market, Takeda's blockbuster attention-deficit/hyperactivity disorder (ADHD) med Vyvanse has finally reached its patent cliff.  The med...

After floating the idea earlier this month, Mallinckrodt has formally declared its intention to kick off another round of bankruptcy proceedings in the coming days.&...

Novo Nordisk is struggling to meet strong demand for Wegovy, and the company has reportedly tapped another contract manufacturer to churn out the popular w...

The FDA has torn into Exeltis over a social media sponsored post for birth control pill Slynd, lambasting the drugmaker for leaving out all the risk information, mak...

Robert Califf, M.D., is “fired up” about the spate of U.S. drug shortages that now constitutes a “national security threat,” the FDA commissioner said Tuesday. “I...

With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pande...

It’s been exactly one year since President Joe Biden signed the Inflation Reduction Act (IRA) and in less than a month, the Center for Medicare & Medicaid Servic...

For three years, Teva has been defending against claims from the U.S. government that it paid illegal kickbacks to boost sales of its multiple sclerosis drug Copaxon...